Table 2.
Association of the TyG index with the absolute change, change rate and slope of baPWV
model 1 | model 2 | model 3 | |||||||
---|---|---|---|---|---|---|---|---|---|
β | 95% CI | P value | β | 95% CI | P value | β | 95% CI | P value | |
Change of baPWV (cm/s) | |||||||||
TyG (continuous) | 32.034 | 4.642–59.425 | 0.022 | 57.119 | 22.835–91.402 | 0.001 | 149.582 | 90.823–208.342 | < 0.001 |
Quartile 2 (ref: quartile 1) | 59.745 | 10.509–108.982 | 0.017 | 61.086 | 12.582–109.59 | 0.014 | 76.297 | 28.63–123.964 | 0.002 |
Quartile 3 | 85.613 | 36.416–134.81 | 0.001 | 93.631 | 43.889–143.373 | < 0.001 | 102.562 | 52.08–153.044 | < 0.001 |
Quartile 4 | 74.957 | 25.494–124.42 | 0.003 | 98.555 | 37.584–159.526 | 0.002 | 129.525 | 58.723–200.326 | < 0.001 |
P for trend | 0.002 | < 0.001 | < 0.001 | ||||||
Change rate of baPWV (cm/s/year) | |||||||||
TyG (continuous) | 11.892 | 3.415–20.368 | 0.006 | 17.974 | 7.307–28.642 | 0.001 | 40.372 | 21.853–58.891 | < 0.001 |
Quartile 2 (ref: quartile 1) | 11.870 | -3.385–27.125 | 0.127 | 12.122 | -2.986–27.229 | 0.116 | 16.529 | 1.507–31.551 | 0.031 |
Quartile 3 | 20.615 | 5.373–35.858 | 0.008 | 22.642 | 7.149–38.135 | 0.004 | 24.390 | 8.481–40.299 | 0.003 |
Quartile 4 | 24.616 | 9.291–39.941 | 0.002 | 30.750 | 11.76–49.741 | 0.002 | 37.607 | 15.294–59.919 | 0.001 |
P for trend | 0.001 | 0.001 | < 0.001 | ||||||
Slope of baPWV | |||||||||
TyG (continuous) | 9.570 | 1.538–17.601 | 0.020 | 14.238 | 4.121–24.355 | 0.006 | 34.874 | 17.238–52.51 | < 0.001 |
Quartile 2 (ref: quartile 1) | 10.986 | -3.469–25.441 | 0.136 | 10.888 | -3.439–25.215 | 0.137 | 14.872 | 0.57–29.175 | 0.042 |
Quartile 3 | 18.739 | 4.296–33.182 | 0.011 | 20.092 | 5.399–34.785 | 0.007 | 22.163 | 7.016–37.31 | 0.004 |
Quartile 4 | 20.126 | 5.604–34.647 | 0.007 | 23.648 | 5.639–41.658 | 0.010 | 30.576 | 9.332–51.82 | 0.005 |
P for trend | 0.004 | 0.003 | 0.002 |
Model 1: Adjusted age and sex; Model 2: Age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP at baseline and follow-up; Model 3: Model 2 plus FBG, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow-up